

# International Nonproprietary Names for Pharmaceutical Substances

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances (see Annexes), the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals Unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 66 Prop. INN not later than 31 August 1992**.

## Proposed International Nonproprietary Names: List 66


*Lists of proposed (1–58) and recommended (1–27) international nonproprietary names can be found in Cumulative List No. 7, 1988.*

Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

albifyllinum  
albifylline

1-(5-hydroxy-5-methylhexyl)-3-methylxanthine  
C<sub>13</sub>H<sub>20</sub>N<sub>4</sub>O<sub>5</sub> 107767-55-5 *polymorphonuclear neutrophil  
modulator*




\* *Action and Use: The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.*

Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


alosetronum  
alosetron

2,3,4,5-tetrahydro-5-methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-  
pyrido[4,3-b]indol-1-one  
C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O 122852-42-0 *antiemetic, anxiolytic*




atovaquonum  
atovaquone

2-[*trans*-4-(*p*-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone  
C<sub>22</sub>H<sub>19</sub>ClO<sub>3</sub> 95233-18-4 *antimalarial*




batebulastum  
batebulast

*p*-*tert*-butylphenyl *trans*-4-(guanidinomethyl)cyclohexanecarboxylate  
C<sub>19</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub> 81907-78-0 *asthmatic*



befloxatonum  
befloxatone

(*R*)-5-(methoxymethyl)-3-[*p*-[(*R*)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-  
oxazolidinone  
C<sub>15</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>5</sub> 134564-82-2 *antidepressant*



Proposed International  
Nonproprietary Name  
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

betadexum  
betadex

$\beta$ -cyclodextrin  
 $C_{42}H_{70}O_{35}$

7585-39-9

pharmaceutical aid



biciromabum  
biciromab

mouse T2G1s cell anti-human fibrin II  $\beta$ -chain monoclonal immunoglobulin G  
Fab' fragment


diagnostic agent

brimonidinum  
brimonidine

5-bromo-6-(2-imidazolidinylidenamino)quinoxaline  
 $C_{11}H_{10}BrN_5$

59803-98-4

$\alpha_2$ -adrenoreceptor agonist




calcii levofolinas  
calcium levofolinate

calcium *N*-[*p*-[[[(6*S*)-2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]-*L*-glutamate (1:1)  
 $C_{20}H_{21}CaN_7O_7$

80433-71-2

antineoplastic




cebaracetamum  
cebaracetam

( $\pm$ )-4-[[4-(*p*-chlorophenyl)-2-oxo-1-pyrrolidinyl]acetyl]-2-piperazinone  
 $C_{16}H_{18}ClN_3O_3$

113957-09-8

nootropic agent




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


cefditorenium  
cefditoren

(+)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-3-[(*Z*)-2-(4-methyl-5-thiazolyl)vinyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7<sup>2</sup>-(*Z*)-(O-methyloxime)  
C<sub>19</sub>H<sub>18</sub>N<sub>6</sub>O<sub>5</sub>S<sub>3</sub> 104145-95-1 antibiotic




cefozopranum  
cefozopran

(-)-1-[[ (6*R*,7*R*)-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido]-2-carboxy-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1*H*-imidazo[1,2-*b*]pyridazin-4-ium hydroxide inner salt, 7<sup>2</sup>-(*Z*)-(O-methyloxime)  
C<sub>19</sub>H<sub>17</sub>N<sub>9</sub>O<sub>5</sub>S<sub>2</sub> 113359-04-9 antibiotic




cilnidipinum  
cilnidipine

(±)-(*E*)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate  
C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>7</sub> 132203-70-4 calcium channel blocker




deriglidolum  
deriglidole

(+)-1,2,4,5-tetrahydro-2-(2-imidazolin-2-yl)-2-propylpyrrolo[3,2,1-*hi*]indole  
C<sub>16</sub>H<sub>21</sub>N<sub>3</sub> 122830-14-2 antidiabetic, α<sub>2</sub>-adrenoreceptor antagonist



dextosfoserinum  
dextosfoserine

L-serine dihydrogen phosphate (ester)  
C<sub>3</sub>H<sub>8</sub>NO<sub>6</sub>P 407-41-0 nootropic agent



Proposed International  
Nonproprietary Name  
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

dorlimomab aritoxum  
dorlimomab aritox

ricin A chain-antibody ST 1 F(ab')<sub>2</sub> fragment immunotoxin  
*immunomodulator*


efonidipinum  
efonidipine

2-(*N*-benzylanilino)ethyl (±)-1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-5-phosphonononate, cyclic 2,2-dimethyltrimethylene ester  
C<sub>34</sub>H<sub>38</sub>N<sub>3</sub>O<sub>7</sub>P 111011-63-3 *calcium channel blocker*




eliprodilum  
eliprodil

(±)-α-(*p*-chlorophenyl)-4-(*p*-fluorobenzyl)-1-piperidineethanol  
C<sub>20</sub>H<sub>23</sub>ClFNO 119431-25-3 *N-methyl-D-aspartate antagonist*




emakalimum  
emakalim

(-)-(3*S*,4*R*)-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2*H*)-pyridyl)-6-chromancarbonitrile  
C<sub>17</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> 129729-66-4 *potassium channel activator*



emitefurum  
emitefur

*m*-[[3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2*H*)-pyrimidinyl]-carbonyl]benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile, benzoate (ester)  
C<sub>28</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>8</sub> 110690-43-2 *antineoplastic*



Proposed International  
Nonproprietary Name  
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

ersoferminum  
ersofermin

*N*-(*N*-glycyl-L-threonyl)basic fibroblast growth factor  
(human clone  $\lambda$ KB7/ $\lambda$ HFL1 precursor reduced)  
 $C_{775}H_{1220}N_{220}O_{223}S_7$  111212-85-2 growth factor


formestanum  
formestane

4-hydroxyandrost-4-ene-3,17-dione  
 $C_{19}H_{26}O_3$  566-48-3 aromatase inhibitor




gadobutrolum  
gadobutrol

[10-[2,3-dihydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)]gadolinium  
 $C_{18}H_{31}GdN_4O_9$  138071-82-6 paramagnetic contrast medium




idraprilum  
idrapril





(1*S*,2*R*)-2-[[[(hydroxycarbonyl)methyl]methyl]carbonyl]cyclohexane-  
carboxylic acid  
 $C_{11}H_{18}N_2O_5$  127420-24-0 angiotensin-converting-enzyme inhibitor



ilatretotidum  
ilatretotide

*N*-(1-deoxy-4-*O*- $\alpha$ -D-giucopyranosyl-D-fructopyranos-1-yl)-D-phenylalanyl-  
L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-*N*-[(1*R*,2*R*)-  
2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2 $\rightarrow$ 7)-disulfide  
 $C_{61}H_{88}N_{10}O_{26}S_2$  antiulcer agent




Proposed International Nonproprietary Name (Latin, English)	Chemical Name or Description, Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use*
imciromabum imciromab	mouse R11D10 cell monoclonal $\alpha$ -chain containing immunoglobulin G2a, anti-human cardiac myosin heavy chain 126132-83-0 <i>immunomodulator</i>
imiquimodum imiquimod	4-amino-1-isobutyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinoline C <sub>14</sub> H <sub>16</sub> N <sub>4</sub> 99011-02-6 <i>antiviral</i>
	
iomazenilum ( <sup>123</sup> I) iomazenil ( <sup>123</sup> I)	ethyl 5,6-dihydro-7-iodo- <sup>123</sup> I-5-methyl-6-oxo-4 <i>H</i> -imidazo[1,5- <i>a</i> ][1,4]benzo = diazepine-3-carboxylate C <sub>15</sub> H <sub>14</sub> <sup>123</sup> IN <sub>3</sub> O <sub>3</sub> 127396-36-5 <i>benzodiazepine-receptor antagonist, diagnostic agent</i>
	
iomolpanum iomolpan	(±)- <i>trans</i> -1,3,4,4a,5,10b-hexahydro-4-propyl-2 <i>H</i> -[1]benzopyrano = [3,4- <i>b</i> ]pyridin-9-ol C <sub>15</sub> H <sub>21</sub> NO <sub>2</sub> 107320-86-5 <i>antipsychotic</i>
	
itopridum itopride	<i>N</i> -[ <i>p</i> -(2-(dimethylamino)ethoxy)benzyl]veratramide C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O <sub>4</sub> 122898-67-3 <i>digestive</i>
	

Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


lamivudinum  
lamivudine

(-)-1-[(2*R*,5*S*)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine  
 $C_8H_{11}N_3O_3S$  134678-17-4 *antiviral*




ianoconazolum  
ianoconazole

(±)-α-[(*E*)-4-(*o*-chlorophenyl)-1,3-dithiolan-2-ylidene]imidazole-1-acetonitrile  
 $C_{14}H_{10}ClN_3S_2$  101530-10-3 *antifungal, dermatological*




lazabemidum  
lazabemide

*N*-(2-aminoethyl)-5-chloropicolinamide  
 $C_8H_{10}ClN_3O$  103878-84-8 *antiparkinsonian*




iesopitronum  
iesopitron

2-[4-[4-(4-chloropyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine  
 $C_{15}H_{21}ClN_6$  132449-46-8 *anxiolytic*



ievcromakalimum  
ievcromakalim

(3*S*,4*R*)-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile  
 $C_{16}H_{15}N_2O_3$  94535-50-9 *potassium channel activator*






Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


lifarizinum  
lifarizine

1-(diphenylmethyl)-4-[(5-methyl-2-*p*-tolylimidazol-4-yl)methyl]piperazine  
C<sub>29</sub>H<sub>32</sub>N<sub>4</sub> 119514-66-8 *vasodilator*



losartanum  
losartan

2-butyl-4-chloro-1-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol  
C<sub>22</sub>H<sub>23</sub>ClN<sub>5</sub>O 114798-26-4 *angiotensin II receptor antagonist*



maslimomabum  
maslimomab


mouse monoclonal immunoglobulin G2b, anti-human T-cell receptor  
 $\alpha/\beta$  chain  
127757-92-0 *immunomodulator*

mecaserminum  
mecasermin

insulin-like growth factor I (human)  
C<sub>331</sub>H<sub>512</sub>N<sub>94</sub>O<sub>101</sub>S<sub>7</sub> 68562-41-4 *growth factor*

miboplatinum  
miboplatin

(-)-*cis*-[(*R*)-2-(aminomethyl)pyrrolidine](1,1-cyclobutanedicarboxylato) =  
platinum  
C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>Pt 103775-75-3 *antineoplastic*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

mosapridum  
mosapride

(±)-4-amino-5-chloro-2-ethoxy-*N*-[[4-(*p*-fluorobenzyl)-2-morpholinyl]=  
methyl]benzamide  
 $C_{21}H_{25}ClFN_3O_3$  112885-41-3 *digestive*



nartograstimum  
nartograstim


*N*-L-methionyl-1-L-alanine-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine =  
colony-stimulating factor (human clone 1034)  
 $C_{850}H_{1344}N_{226}O_{245}S_8$  134088-74-7 *immunomodulator*  
(for non-glycosylated protein)

nebacumabum  
nebacumab

immunoglobulin M (human monoclonal HA-1A anti-endotoxin), disulfide with  
human monoclonal HA-1A  $\alpha$ -chain, pentameric dimer  
138661-01-5 *immunomodulator*


necopidemum  
necopidem

*N*-[[2-(*p*-ethylphenyl)-6-methylimidazo[1,2-*a*]pyridin-3-yl]methyl]-*N*,3-  
dimethylbutyramide  
 $C_{23}H_{29}N_3O$  103844-77-5 *anaesthetic*



nevirapinum  
nevirapine

11-cyclopropyl-5,11-dihydro-4-methyl-6*H*-dipyrido[3,2-*b*:2',3'-*e*][1,4]diazepin-  
6-one  
 $C_{15}H_{14}N_4O$  129618-40-2 *antiviral*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


odalprofenum  
odalprofen

methyl (+)-*m*-( $\alpha$ -imidazol-1-ylbenzyl)hydratropate  
 $C_{20}H_{20}N_2O_2$  137460-88-9 *nonsteroidal anti-inflammatory, analgesic*




tetreotidum  
pentetreotide

*N*-[2-[[2-bis(carboxymethyl)amino]ethyl](carboxymethyl)amino]ethyl]-*N*-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-*N*-[(1*R*,2*R*)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (3→8)-disulfide  
 $C_{63}H_{67}N_{13}O_{19}S_2$  138661-02-6 *diagnostic agent, antineoplastic*




perflubronum  
perflubron

1-bromoheptadecafluorooctane  
 $C_8BrF_{17}$  423-55-2 *contrast medium*




perfosamidum  
perfosamide

(±)-*cis*-2-[bis(2-chloroethyl)amino]tetrahydro-2*H*-1,3,2-oxazaphosphorin-4-yl hydroperoxide, *P*-oxide  
 $C_7H_{15}Cl_2N_2O_4P$  62435-42-1 *antineoplastic*



pivagabinum  
pivagabine

4-pivalamidobutyric acid  
 $C_9H_{17}NO_3$  69542-93-4 *antiparkinsonian, anticonvulsant*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

plomestatum  
plomestane


10-(2-propynyl)estr-4-ene-3,17-dione  
 $C_{21}H_{26}O_2$  77016-85-4

antineoplastic



polaprezincum  
polaprezinc

catena-poly[zinc-μ-[β-alanyl-L-histidinato(2-)-N,N',O:N<sup>+</sup>]]  
( $C_9H_{12}N_4O_5Zn$ )<sub>n</sub> 107667-60-7 antiulcer agent




poliglecapronum  
poliglecaprone

2-oxepanone polymer with *p*-dioxane-2,5-dione

"*m*" and "*n*" are the numerical values representing the mol percentages of the monomers. The value of "*m*" should be given as a figure after the INN, e.g. "poliglecaprone 90", which means "*m* = 90" and "*n* = 10".

( $C_6H_{10}O_2$ )<sub>m</sub>( $C_4H_4O_4$ )<sub>n</sub> 41706-81-4

pharmaceutical aid




poliglusamum  
poliglusam

chitosan

9012-76-4


haemostatic



pranidipinum  
pranidipine

(*E*)-cinnamyl methyl (±)-1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate  
 $C_{23}H_{24}N_2O_6$  99522-79-9

calcium channel blocker



Proposed International  
Nonproprietary Name  
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

racephedrinum  
racephedrine

(±)-ephedrine  
C<sub>10</sub>H<sub>15</sub>NO

90-81-3

sympathomimetic




remikirenium  
remikiren

(αS)-α-[(αS)-α-[(*tert*-butylsulfonyl)methyl]hydrocinnamamido]-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]imidazole-4-propionamide  
C<sub>33</sub>H<sub>50</sub>N<sub>4</sub>O<sub>6</sub>S

126222-34-2

renin inhibitor




rocuronii bromidum  
rocuronium bromide

1-allyl-1-(3α,17β-dihydroxy-2β-morpholino-5α-androstan-16β-yl)pyrrolidinium bromide, 17-acetate  
C<sub>32</sub>H<sub>53</sub>BrN<sub>2</sub>O<sub>4</sub>

119302-91-9

neuromuscular receptor antagonist







romergolinum  
romergoline

4-[(9,10-didehydro-6-methylergolin-8β-yl)methyl]-2,6-piperazinedione  
C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>

107052-56-2

antiparkinsonian, antipsychotic




<i>Proposed International Nonproprietary Name (Latin, English)</i>	<i>Chemical Name or Description, Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use*</i>
sargramostimum sargramostim	23-L-leucinecolony-stimulating factor 2 (human clone pHG25 protein moiety) $C_{639}H_{1002}N_{168}O_{196}S_8$ 123774-72-1 (for non-glycosylated protein) <i>immunomodulator</i>
seproxetinum seproxetine	( <i>S</i> )-3-phenyl-3-[( <i>a,a,a</i> -trifluoro- <i>p</i> -tolyl)oxy]propylamine $C_{16}H_{16}F_3NO$ 126924-38-7 <i>antidepressant</i>
	
sevirumabum sevirumab	human monoclonal immunoglobulin G1, $\kappa$ -chain, anti-cytomegavirus <i>immunomodulator</i>
simendanum simendan	mesoxalonitrile ( $\pm$ )-[ <i>p</i> -(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazone $C_{14}H_{12}N_6O$ 131741-08-7 <i>cardiac stimulant</i>
	
somfaseporum somfasepor	8-190 growth hormone (pig) $C_{938}H_{1445}N_{257}O_{278}S_6$ 129566-95-6 <i>growth hormone (vet.)</i>
tacrolimusum tacrolimus	(-)-(3 <i>S</i> ,4 <i>R</i> ,5 <i>S</i> ,8 <i>R</i> ,9 <i>E</i> ,12 <i>S</i> ,14 <i>S</i> ,15 <i>R</i> ,16 <i>S</i> ,18 <i>R</i> ,19 <i>R</i> ,26 <i>aS</i> )-8-allyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26 <i>a</i> -hexadecahydro-5,19-dihydroxy-3-[( <i>E</i> )-2-[(1 <i>R</i> ,3 <i>R</i> ,4 <i>R</i> )-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3 <i>H</i> -pyrido[2,1- <i>c</i> ][1,4]oxa-azacyclotricosine-1,7,20,21(4 <i>H</i> ,23 <i>H</i> )-tetrone $C_{44}H_{69}NO_{12}$ 104987-11-3 <i>immunosuppressant</i>
	

Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

tamolarizinium  
tamolarizine

(±)-α-(3,4-dimethoxyphenyl)-4-(diphenylmethyl)-1-piperazineethanol  
C<sub>27</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub> 128229-52-7 *nootropic agent*




telimomabum aritoxum  
telimomab aritox

ricin A chain-antibody T 101 Fab fragment immunotoxin  
117305-33-6 *immunosuppressant*


terlakirenum  
terlakiren

isopropyl (αR,βS)-α-hydroxy-β-[(R)-3-(methylthio)-2-[(S)-α-4-morpholinecarboxamidohydrocinnamamido]propionamido] = cyclohexanecarboxylate  
C<sub>31</sub>H<sub>48</sub>N<sub>4</sub>O<sub>7</sub>S 119625-78-4 *renin inhibitor*




tetrofosminum  
tetrofosmin

ethylenebis[bis(2-ethoxyethyl)phosphine]  
C<sub>18</sub>H<sub>40</sub>O<sub>4</sub>P<sub>2</sub> 127502-06-1 *diagnostic agent*



toicaponium  
toicapone

3,4-dihydroxy-4'-methyl-5-nitrobenzophenone  
C<sub>14</sub>H<sub>11</sub>NO<sub>5</sub> 134308-13-7 *antiparkinsonian*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


tretinoinum tocoferilum  
tretinoin tocoferil

(±)-(2*R*\*)-2,5,7,8-tetramethyl-2-[(4*R*\*,8*R*\*)-4,8,12-trimethyltridecyl]-6-  
chromanyl retinoate  
 $C_{49}H_{76}O_3$  40516-48-1 *vitamin*




trimegestonum  
trimegestone

17β-(*S*)-lactoyl-17-methylestra-4,9-dien-3-one  
 $C_{22}H_{30}O_3$  74513-62-5 *progestogen*



tucaresolum  
tucaresol

α-(2-formyl-3-hydroxyphenoxy)-*p*-toluic acid  
 $C_{15}H_{12}O_5$  84290-27-7 *antianaemic*




tuvirumabum  
tuvirumab

human monoclonal immunoglobulin G1, λ-chain, anti-hepatitis B virus  
surface antigen  
*immunomodulator*

unoprostonum  
unoprostone

(+)-(Z)-7-[(1*R*2*R*,3*R*,5*S*)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-  
heptenoic acid  
 $C_{22}H_{38}O_5$  120373-36-6 *antiglaucoma*






Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


velaresolum  
velaresol

5-(2-formyl-3-hydroxyphenoxy)valeric acid  
 $C_{12}H_{14}O_5$  77858-21-0 *antianaemic*




zalcitabinum  
zalcitabine

2',3'-dideoxycytidine  
 $C_9H_{13}N_3O_3$  7481-89-2 *antiviral*




zaldaridum  
zaldaride

(±)-1-[1-[(4-methyl-4*H*,6*H*-pyrrolo[1.2-*a*][4,1]benzoxazepin-4-yl)methyl]-4-piperidyl]-2-benzimidazolinone  
 $C_{26}H_{28}N_4O_2$  109826-26-8 *antidiarrhoeal*



zoniclezolum  
zoniclezole

5-chloro-3-(1-imidazol-1-ylethyl)-1,2-benzisoxazole  
 $C_{12}H_{10}ClN_3O$  121929-20-2 *anticonvulsant*




## Names for Radicals and Groups

Some substances for which a proposed International Nonproprietary Name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed International Nonproprietary Names.

buciclas  
buciclate

*trans*-4-butylcyclohexanecarboxylate  
 $C_{11}H_{19}O_2$



# AMENDMENTS TO PREVIOUS LISTS

Supplement to WHO Chronicle, Vol. 34, No. 9, 1980

## Proposed International Nonproprietary Names (Prop. INN): List 44

p. 12 felodipinum  
felodipine

replace the chemical name and the CAS registry number by the following:

(±)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-  
3,5-pyridinedicarboxylate  
86189-69-7


Supplement to WHO Chronicle, Vol. 39, No. 5, 1985

## Proposed International Nonproprietary Names (Prop. INN): List 53

p. 12 glimepiridum  
glimepiride

replace the chemical name and the graphic formula by the following:

1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)=  
ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea



WHO Drug Information, Vol. 1, No. 2, 1987

## Proposed International Nonproprietary Names (Prop. INN): List 57

p. 104 ramoplaninum  
ramoplanin

replace the description, molecular formula and CAS registry number by the following:

glycopeptide antibiotic produced by *actinoplanes* species ATCC33076  
Ramoplanin is a complex antibiotic consisting of a main component  
designated as ramoplanin A<sub>2</sub> and a small amount of related substances,  
ramoplanin A<sub>1</sub> and A<sub>3</sub>.  
C<sub>112-120</sub>H<sub>142-156</sub>ClN<sub>21</sub>O<sub>35-40</sub> 76168-82-6

WHO Drug Information, Vol. 2, No. 4, 1988

## Proposed International Nonproprietary Names (Prop. INN): List 60

p. 15 delete

orlipastatum  
orlipastat

insert

orlistatum  
orlistat

WHO Drug Information, Vol. 3, No. 4, 1989


**Proposed International Nonproprietary Names (Prop. INN): List 62**

p. 6	epoetin alfa epoetin alfa	replace the description by the following: human 1-165-erythropoietin, glycoform $\alpha$
------	------------------------------	---

WHO Drug Information, Vol. 4, No. 2, 1990

**Proposed International Nonproprietary Names (Prop. INN): List 63**

p. 4	cilobradinum cilobradine	delete the CAS registry number and replace the chemical name and the graphic formula by the following: (+)-(S)-3-[[1-(3,4-dimethoxyphenethyl)-3-piperidyl]methyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one
------	-----------------------------	---



WHO Drug Information, Vol. 4, No. 4, 1990

**Proposed International Nonproprietary Names (Prop. INN): List 64**

p. 7	corticoirelinum corticorlin	replace the description, molecular and graphic formula by the following: corticotropin-releasing factor; the species specificity should be indicated in brackets behind the name e.g .
------	--------------------------------	---

corticoirelin (human)

$C_{208}H_{344}N_{60}O_{63}S_2$

H — Ser — Glu — Glu — Pro — Pro — Ile — Ser — Leu — Asp — Leu — Thr — Phe — His — Leu —  
Leu — Arg — Glu — Val — Leu — Glu — Met — Ala — Arg — Ala — Glu — Gln — Leu — Ala —  
Gln — Gln — Ala — His — Ser — Asn — Arg — Lys — Leu — Met — Glu — Ile — Ile —  $NH_2$

corticoirelin (ovine)


$C_{205}H_{339}N_{59}O_{63}S$

H — Ser — Gln — Glu — Pro — Pro — Ile — Ser — Leu — Asp — Leu — Thr — Phe —  
His — Leu — Leu — Arg — Glu — Val — Leu — Glu — Met — Thr — Lys — Ala —  
Asp — Gln — Leu — Ala — Gln — Gln — Ala — His — Ser — Asn — Arg — Lys —  
Leu — Leu — Asp — Ile — Ala —  $NH_2$

p. 12	lenograstimum lenograstim	insert the following CAS registry number: 135968-09-1
-------	------------------------------	--

p. 20 racementolum  
racementol

replace the graphic formula by the following:



p. 27 fendizoatum  
fendizoate

delete the CAS registry number:

p. 27 loprazolamum  
loprazolam

replace the CAS registry number by the following:


61197-73-7

## WHO Drug Information, Vol. 5, No. 2, 1991

### Proposed International Nonproprietary Names (Prop. INN): List 65

p. 9 naglivanum  
naglivan

replace the graphic formula by the following:




p. 10 polifeprosanum  
polifeprosan

add the following:

"m" and "n" are the numerical values representing the mass percentages of the monomers. The value of "m" should be given as a figure after the INN, e.g. "polifeprosan 20", which means "m = 20" and "n = 80".

p. 17 cetorelixum  
cetorelix

replace the graphic formula by the following:



p. 19 terikalantum  
terikalant

replace the chemical name by the following:

(-)-(S)-1-[2-(4-chromanyl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine

### Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* appeared in list 65 of proposed INN and will appear again in the next list.